Ticker Details
Editas Medicine, Inc. Editas Medicine Inc is a genome editing company which is engaged in treating patients with genetically defined diseases by correcting disease-causing genes.
IPO Date:	February 3, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$282.85M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.68 | 3.40%
Avg Daily Range (30 D):	$0.09 | 4.07%
Avg Daily Range (90 D):	$0.08 | 3.71%

Institutional Daily Volume
Avg Daily Volume:	1.32M
Avg Daily Volume (30 D):	1.59M
Avg Daily Volume (90 D):	1.61M

Trade Size
Avg Trade Size (Sh.):	114
Avg Trade Size (Sh.) (30 D):	165
Avg Trade Size (Sh.) (90 D):	191

Institutional Trades
Total Institutional Trades:	3,815
Avg Institutional Trade:	$2.01M
Avg Institutional Trade (30 D):	$1.05M
Avg Institutional Trade (90 D):	$1.39M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.78M
Avg Closing Trade (30 D):	$1.05M
Avg Closing Trade (90 D):	$1.39M
Avg Closing Volume:	160.45K

News

Mar 9, 2026 @ 11:00 AM Editas Medicine Announces Fourth Quarter and Full ... Source: Na

Jan 22, 2026 @ 9:56 AM Genome Editing Market Forecast to Reach $23.6 Bill... Source: Researchandmarkets.Com

Nov 17, 2025 @ 3:00 PM Gene Therapies for Cancer Treatment Market Project... Source: Towards Healthcare

Sep 25, 2025 @ 1:15 PM Healthcare Innovation Accelerates as Four Convergi... Source: Prnewswire

Sep 2, 2025 @ 10:00 AM Gene Editing Market to Surpass USD 15.46 Billion b... Source: Sns Insider

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-1.8	$	$-1.8
Diluted EPS	$-1.8	$	$-1.8
Revenue	$40.52M	$24.74M	$40.52M
Gross Profit
Net Income / Loss	$-160.06M	$-5.62M	$-160.06M
Operating Income / Loss	$-160.01M	$-7.76M	$-160.01M
Cost of Revenue
Net Cash Flow	$13.9M	$-19M	$13.9M
PE Ratio